Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1301 in Synovial Sarcoma
NCT03250325Phase 2Completed
- Sponsor
- Takara Bio Inc.
- Start
- Sep 2017
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-NY-ESO-1 TCR-T in synovial sarcoma (SS), sponsored by Takara Bio Inc.. Started Sep 2017; status: completed.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT03250325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250325.